The PSMA toolkit is further expanded with tracer development, such as the use of [^18F]PSMA-1007 to detect local relapse in specific situations (18) and network meta-analyses to combine the evidence of modalities and prostate cancer treatment steps (19). This evidence concerns the gene FOLH1 and Familial prostate cancer.